SCHEMBL2800993

SCHEMBL2800993

CNC(=O)c1cc(=O)n(CCN2CCC(N(C)c3sc4ccccc4c3Cl)CC2)c2cc(OC)ccc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 3/20 0.39
PRSS12 P56730 2/20 0.37
KCNH2 Q12809 1/20 0.37
ALDH1A1 P00352 2/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CCR5 P51681 2/20 0.36
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
MAOB P27338 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2794876 0.92 KCNH2 (0.39) NPY1RKCNH2ALDH1A1HPGDCCR5
Hydrochloric Acid SCHEMBL2798696 0.85 KCNH2 (0.37) KCNH2ALDH1A1HPGDCCR5DRD2
SCHEMBL2800992 0.84 KCNH2 (0.46) PRSS12KCNH2ALDH1A1THRBHPGD
SCHEMBL2798891 0.82 KCNH2 (0.38) KCNH2ALDH1A1HPGDCNR1CNR2
SCHEMBL2797739 0.81 KCNH2 (0.40) KCNH2ALDH1A1HPGDDRD3CNR1
SCHEMBL2796334 0.81 MCHR1 (0.39) KCNH2ALDH1A1HPGDNPC1RAB9A
SCHEMBL2798996 0.81 KCNH2 (0.36) KCNH2MAOBCNR1CNR2
Hydrochloric Acid SCHEMBL2799106 0.81 KCNH2 (0.37) KCNH2ALDH1A1LMNACCR5DRD2
SCHEMBL2799217 0.80 KCNH2 (0.39) KCNH2ALDH1A1HPGDCNR1CNR2
SCHEMBL2796533 0.80 KCNH2 (0.39) KCNH2ALDH1A1HPGDMAOBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-23 US disclosed
EP-2468743-A1 Nitrogen-containing bicyclic compounds useful as antibacterial agents Toyama Chemical Co., Ltd. (JP) 2012-06-27 EP disclosed
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2010-07-01 US disclosed
EP-1900732-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2008-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF ROS1, NOX1, ARG1 NPY1R 539/4885PRSS12 1756/4885KCNH2 578/4885
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION NQO2, ASNS, NDUFS1 NPY1R 3099/4885PRSS12 1586/4885KCNH2 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.